+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Generic Drugs - Global Market Trajectory & Analytics

  • ID: 5309456
  • Report
  • February 2022
  • Region: Global
  • 641 Pages
  • Global Industry Analysts, Inc

FEATURED COMPANIES

  • Abbott Laboratories
  • Baxter International Inc.
  • F. Hoffmann-La Roche AG
  • H. Lundbeck A/S
  • Novartis International AG
  • Sanofi-Aventis U.S. LLC

Global Generic Drugs Market to Reach $507.8 Billion by 2026


Amid the COVID-19 crisis, the global market for Generic Drugs estimated at US$365.9 Billion in the year 2020, is projected to reach a revised size of US$507.8 Billion by 2026, growing at a CAGR of 5.6% over the analysis period. Small-Molecule Generics, one of the segments analyzed in the report, is projected to grow at a 5.2% CAGR to reach US$325.7 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Biosimilars segment is readjusted to a revised 6.3% CAGR for the next 7-year period. This segment currently accounts for a 37.7% share of the global Generic Drugs market.



The U.S. Market is Estimated at $116.2 Billion in 2021, While China is Forecast to Reach $91.2 Billion by 2026


The Generic Drugs market in the U.S. is estimated at US$116.2 Billion in the year 2021. The country currently accounts for a 30.46% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$91.2 Billion in the year 2026 trailing a CAGR of 7.2% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.8% and 5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR while Rest of European market (as defined in the study) will reach US$97.6 Billion by the close of the analysis period.

The market is expected to be driven by the steadily rising risk of various chronic diseases such as hypertension, obesity and diabetes. Though pharma companies continue to develop branded drugs due to the dearth of new blockbuster drugs coming into the marketplace, generic drugs are expected to continue meeting the majority of these therapeutic needs of the population, especially the expanding elderly population. With high cost of branded medication becoming a financial burden for people, efforts have intensified to develop cost effective generic variants. Several branded drugs are unable to extend their exclusivity leading to loss of patents and giving way to the manufacture of affordable generics. Major application areas for generic drugs include cardiology, anti-infection, anti-arthritis, CNS, anti-cancer and respiratory among others. Generic drugs for CVDs represent the dominant segment currently, accounting for majority share in the overall market. Cardiovascular diseases such as heart failure, high BP, circulatory disorders, dyslipidemia, cholesterol, arrhythmias, stroke and angina are the major causes of global deaths. The cardiovascular segment is expected to cover a larger part of the global generic drug market owing to several patent expirations of these drugs. Generic drugs for infectious diseases would gain much traction over the coming years mainly because of increasing number of cases worldwide. The COVID-19 pandemic emerged as a significant growth driver for generic drugs market over the past one year. As economies of nations crashed because of increasing unemployment, the demand for cheaper substitutes of branded drugs increased.

Select Competitors (Total 42 Featured) -

  • Abbott Laboratories
  • Apotex Inc.
  • ASKA Pharmaceutical Co., Ltd.
  • Aspen Pharmacare Holdings Limited
  • AstraZeneca Plc
  • Baxter International Inc.
  • Dr. Reddy’s Laboratories Limited
  • Eli Lilly and Company
  • Endo International plc
  • Fresenius Kabi
  • GlaxoSmithKline Plc.
  • H. Lundbeck A/S
  • Hospira
  • Lupin Pharmaceuticals, Inc.
  • Mylan N.V.
  • Novartis International AG
  • Novo Nordisk A/S
  • F. Hoffmann-La Roche AG
  • Sandoz International GmbH
  • Sanofi-Aventis U.S. LLC
  • STADA Arzneimittel AG
  • Sun Pharma
  • Teva Pharmaceutical Industries Ltd.
Frequently Asked Questions about the Global Market for Generic Drugs

What is the estimated value of the Global Market for Generic Drugs?

The Global Market for Generic Drugs was estimated to be valued at $365.9 Billion in 2020.

What is the growth rate of the Global Market for Generic Drugs?

The growth rate of the Global Market for Generic Drugs is 5.6%, with an estimated value of $507.8 Billion by 2026.

What is the forecasted size of the Global Market for Generic Drugs?

The Global Market for Generic Drugs is estimated to be worth $507.8 Billion by 2026.

Who are the key companies in the Global Market for Generic Drugs?

Key companies in the Global Market for Generic Drugs include Abbott Laboratories, Apotex Inc., ASKA Pharmaceutical Co., Ltd., Aspen Pharmacare Holdings Limited, AstraZeneca Plc, Baxter International Inc., Dr. Reddy’s Laboratories Limited, Eli Lilly and Company and Fresenius Kabi.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • Baxter International Inc.
  • F. Hoffmann-La Roche AG
  • H. Lundbeck A/S
  • Novartis International AG
  • Sanofi-Aventis U.S. LLC

I. METHODOLOGY


II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Generic Drugs – Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
  • The Race Between the Virus & Vaccines Intensifies. Amidst this Chaotic Battle, Where is the World Economy Headed in 2021?
  • How Fast the World is Vaccinated Will Determine How Soon the Pandemic Will End: Global Number of Annual COVID-19 Vaccine Doses (In Million) for Years 2020 through 2025 by Geographic Region/Country
  • Progress on Vaccinations, Why Should Businesses Care?
  • These are Times When Questions Abound & Answers Are Few
  • With IMF’s Upward Revision of Global GDP Forecasts for 2021, Most Companies Are Bullish About a Global Economic Comeback.
  • A Strong 2021 Economic Rebound Based On Pent-Up Demand Comes as a Relief for Suffering Industries & Markets: World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022
  • How the Healthcare Industry Has & Continues to be Impacted by the Pandemic & What’s the New Normal?
  • With the COVID-19 Pandemic Exposing Global Healthcare Unpreparedness, There is Increasing Policy Led Focus on Rebooting Health Systems Worldwide: Current & Required Healthcare Spending as % of GDP
  • Impact of COVID-19 Crisis on Generic Drugs Market
  • Demand for Generic Pain Killers Rises
  • A Prelude to Generic Drugs
  • Generic Drugs Market Set for a Rapid Growth
  • US Dominates, Asia-Pacific to Exhibit the Fastest Growth
  • India- A Significant Market
  • Market Restraints
  • Competition
  • Recent Market Activity

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

  • Patent Expiries Set to Widen the Addressable Market for Generic Drugs
  • Patent Expiries of Select Drugs in 2020
  • Patent Expiries of Select Drugs in 2021
  • Patent Expiries of Select Drugs in 2022
  • Patent Expiry of Select Major Drugs in the US: 2020-2022
  • Robust Demand for Pharmaceutical Drugs Drives Demand for Generic Drugs
  • Cost Containment Measures Put Focus on Generics
  • Small Molecule Generics Represent the Dominant Segment
  • Increasing Demand for Biosimilars, Driven by Patent Expiry of Major Biopharmaceutical Drugs
  • Patent Expiries of Major Biopharmaceutical Drugs in the US and Europe
  • Progressive Regulatory Framework Accelerates Product Approvals & Subsequently Market Revenues
  • Specific Guidelines for Biosimilars in Various Countries with Year of Publication
  • Biosimilars Regulatory Agencies in Select Regional Markets
  • Biosimilar Approvals in the US (as of February 2021)
  • Biosimilar Approvals in Europe (as of January 2021)
  • Rising Healthcare Costs Drive Demand for Generic Drugs
  • World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
  • Aging Population to Propel the Demand for Generic Drugs
  • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
  • Rising Prevalence of Chronic Diseases Drive the Demand for Generic Drugs
  • Global Cost of Chronic Diseases (In US$ Billion) for the Years 2018 and 2030
  • Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
  • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
  • Number of New Cancer Cases and Deaths (in Million) by Region for 2018

4. GLOBAL MARKET PERSPECTIVE

  • A Prelude to Generic Drugs

III. MARKET ANALYSIS

UNITED STATES

  • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)

CANADA

JAPAN

  • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)

CHINA

  • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)

EUROPE

  • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)

FRANCE

  • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)

GERMANY

  • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)

ITALY

UNITED KINGDOM

  • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)

SPAIN


RUSSIA


REST OF EUROPE

ASIA-PACIFIC

  • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)

AUSTRALIA

  • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2022 (E)

INDIA

  • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2022 (E)

SOUTH KOREA


REST OF ASIA-PACIFIC

LATIN AMERICA

  • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2022 (E)

ARGENTINA


BRAZIL


MEXICO


REST OF LATIN AMERICA

MIDDLE EAST

  • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2022 (E)

IRAN


ISRAEL


SAUDI ARABIA


UNITED ARAB EMIRATES


REST OF MIDDLE EAST

AFRICA

  • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2022 (E)

IV. COMPETITION

  • Total Companies Profiled: 42
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Abbott Laboratories
  • Apotex Inc.
  • ASKA Pharmaceutical Co., Ltd.
  • Aspen Pharmacare Holdings Limited
  • AstraZeneca Plc
  • Baxter International Inc.
  • Dr. Reddy’s Laboratories Limited
  • Eli Lilly and Company
  • Endo International plc
  • Fresenius Kabi
  • GlaxoSmithKline Plc.
  • H. Lundbeck A/S
  • Hospira
  • Lupin Pharmaceuticals, Inc.
  • Mylan N.V.
  • Novartis International AG
  • Novo Nordisk A/S
  • F. Hoffmann-La Roche AG
  • Sandoz International GmbH
  • Sanofi-Aventis U.S. LLC
  • STADA Arzneimittel AG
  • Sun Pharma
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown